263 related articles for article (PubMed ID: 32854313)
1. Molecular Pharmacology of Synthetic Cannabinoids: Delineating CB1 Receptor-Mediated Cell Signaling.
Walsh KB; Andersen HK
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854313
[TBL] [Abstract][Full Text] [Related]
2. Molecular signaling of synthetic cannabinoids: Comparison of CB1 receptor and TRPV1 channel activation.
Andersen HK; Walsh KB
Eur J Pharmacol; 2021 Sep; 907():174301. PubMed ID: 34224700
[TBL] [Abstract][Full Text] [Related]
3. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
Castaneto MS; Gorelick DA; Desrosiers NA; Hartman RL; Pirard S; Huestis MA
Drug Alcohol Depend; 2014 Nov; 144():12-41. PubMed ID: 25220897
[TBL] [Abstract][Full Text] [Related]
4. Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors.
Noble C; Cannaert A; Linnet K; Stove CP
Drug Test Anal; 2019 Mar; 11(3):501-511. PubMed ID: 30280499
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
6. Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events.
Davidson C; Opacka-Juffry J; Arevalo-Martin A; Garcia-Ovejero D; Molina-Holgado E; Molina-Holgado F
Adv Pharmacol; 2017; 80():135-168. PubMed ID: 28826533
[TBL] [Abstract][Full Text] [Related]
7. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
8. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF
J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157
[TBL] [Abstract][Full Text] [Related]
9. A real time screening assay for cannabinoid CB1 receptor-mediated signaling.
Andersen HK; Piroli GG; Walsh KB
J Pharmacol Toxicol Methods; 2018; 94(Pt 1):44-49. PubMed ID: 29730318
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
11. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
[TBL] [Abstract][Full Text] [Related]
12. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135.
Banister SD; Stuart J; Kevin RC; Edington A; Longworth M; Wilkinson SM; Beinat C; Buchanan AS; Hibbs DE; Glass M; Connor M; McGregor IS; Kassiou M
ACS Chem Neurosci; 2015 Aug; 6(8):1445-58. PubMed ID: 25921407
[TBL] [Abstract][Full Text] [Related]
13. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.
Marusich JA; Gamage TF; Zhang Y; Akinfiresoye LR; Wiley JL
Pharmacol Biochem Behav; 2022 Oct; 220():173467. PubMed ID: 36154844
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
Zhou H; Peng X; Hou T; Zhao N; Qiu M; Zhang X; Liang X
J Ethnopharmacol; 2020 Jan; 246():112218. PubMed ID: 31494202
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors.
Gamage TF; Farquhar CE; McKinnie RJ; Kevin RC; McGregor IS; Trudell ML; Wiley JL; Thomas BF
J Pharmacol Exp Ther; 2019 Mar; 368(3):414-422. PubMed ID: 30552295
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues.
Banister SD; Longworth M; Kevin R; Sachdev S; Santiago M; Stuart J; Mack JB; Glass M; McGregor IS; Connor M; Kassiou M
ACS Chem Neurosci; 2016 Sep; 7(9):1241-54. PubMed ID: 27421060
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms underlying cannabinoid inhibition of presynaptic Ca2+ influx at parallel fibre synapses of the rat cerebellum.
Daniel H; Rancillac A; Crepel F
J Physiol; 2004 May; 557(Pt 1):159-74. PubMed ID: 15034129
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptor 1 ligands revisited: Pharmacological assessment in the ACTOne system.
Presley CS; Abidi AH; Moore BM
Anal Biochem; 2016 Apr; 498():8-28. PubMed ID: 26772161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
